Hodgkin lymphoma: An update on its biology with new insights into classification

Clinical Lymphoma and Myeloma

Volumn 9, Issue 3, 2009, Pages 206-216

  Mani, Haresh ^a   Jaffe, Elaine ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Classical Hodgkin's lymphoma; Epstein Barr virus; HIV; Immunophenotype; Nodular lymphocyte predominant disease; Primary mediastinal large B cell lymphoma

Indexed keywords

ANTIRETROVIRUS AGENT; CINTREDEKIN BESUDOTOX; EOTAXIN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERFERON; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 3; INTERLEUKIN 5; INTERLEUKIN 6; INTERLEUKIN 9; RITUXIMAB; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TISSUE INHIBITOR OF METALLOPROTEINASE 1; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE;

ATAXIA TELANGIECTASIA; B CELL LYMPHOMA; BLOOM SYNDROME; CANCER CHEMOTHERAPY; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CD4+ T LYMPHOCYTE; CELL INFILTRATION; CLASSICAL HODGKIN LYMPHOMA; CLINICAL FEATURE; COMPARATIVE STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; EPSTEIN BARR VIRUS; EVENT FREE SURVIVAL; GENETIC PREDISPOSITION; GEOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOGENESIS; HISTOPATHOLOGY; HODGKIN DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE RESPONSE; IMMUNOPATHOLOGY; LARGE CELL LYMPHOMA; LYMPHOCYTE DEPLETION HODGKIN LYMPHOMA; LYMPHOCYTE RICH CLASSICAL HODGKIN LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MIXED CELLULARITY HODGKIN LYMPHOMA; NODULAR LYMPHOCYTE PREDOMINANT HODGKIN LYMPHOMA; NODULAR SCLEROSIS HODGKIN LYMPHOMA; OVERALL SURVIVAL; PROGNOSIS; REED STERNBERG CELL; REVIEW; SOCIOECONOMICS; TUMOR CELL; VIRUS INFECTION; WISKOTT ALDRICH SYNDROME; ADOLESCENT; ADULT; APOPTOSIS; CLASSIFICATION; FEMALE; GENETICS; IMMUNOPHENOTYPING; LYMPHOCYTE; MALE; METABOLISM; SOCIAL CLASS;

ADOLESCENT; ADULT; APOPTOSIS; CYTOKINES; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HERPESVIRUS 4, HUMAN; HIV INFECTIONS; HODGKIN DISEASE; HUMANS; IMMUNOPHENOTYPING; LYMPHOCYTES; LYMPHOMA, B-CELL; MALE; SOCIAL CLASS;

EID: 69149102536     PISSN: 15579190     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLM.2009.n.042     Document Type: Review

References (204)

1. Wilks S. Unpublished papers of Thomas Hodgkin. Bull N Y Acad Med 1970; 46:67-9.
2. Kass EH, Bartlett AH. Thomas Hodgkin, M. D. (1798-1866): an annotated bibliography. Bull Hist Med 1969; 43:138-75.
3. Stat bite: U.S. incidence of childhood Hodgkin lymphoma by age group, 1975-2002. J Natl Cancer Inst 2006; 98:7.
4. Jaffe ES, Harris NL, Stein H, et al. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2001.
5. Engert A, Ballova V, Haverkamp H, et al. Hodgkin's lymphoma in elderly patients: a comprehensive retrospective analysis from the German Hodgkin's Study Group. J Clin Oncol 2005; 23:5052-60.
6. Cozen W, Katz J, Mack TM. Risk patterns of Hodgkin's disease in Los Angeles vary by cell type. Cancer Epidemiol Biomarkers Prev 1992; 1:261-8.
7. Clavel J, Steliarova-Foucher E, Berger C, et al. Hodgkin's disease incidence and survival in European children and adolescents (1978-1997): report from the Automated Cancer Information System project. Eur J Cancer 2006; 42:2037-49.
8. Biggar RJ, Jaffe ES, Goedert JJ, et al. Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. Blood 2006; 108:3786-91.
9. Rosenwald A, Wright G, Leroy K, et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198:851-62.
10. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2003; 102:3871-9.
11. Traverse-Glehen A, Pittaluga S, Gaulard P, et al. Mediastinal gray zone lymphoma: the missing link between classic Hodgkin's lymphoma and mediastinal large B-cell lymphoma. Am J Surg Pathol 2005; 29:1411-21.
12. Hsi ED, Sup SJ, Alemany C, et al. MAL is expressed in a subset of Hodgkin lymphoma and identifies a population of patients with poor prognosis. Am J Clin Pathol 2006; 125:776-82.
13. Devilard E, Bertucci F, Trempat P, et al. Gene expression profiling defines molecular subtypes of classical Hodgkin's disease. Oncogene 2002; 21:3095-102.
14. Levy A, Armon Y, Gopas J, et al. Is classical Hodgkin's disease indeed a single entity? Leuk Lymphoma 2002; 43:1813-8.
15. Levy A, Diomin V, Gopas J, et al. Hodgkin's lymphoma in the Bedouin of southern Israel: epidemiological and clinical features. Isr Med Assoc J 2000; 2:501-3.
16. Ohshima K, Akaiwa M, Umeshita R, et al. Interleukin-13 and interleukin-13 receptor in Hodgkin's disease: possible autocrine mechanism and involvement in fibrosis. Histopathology 2001; 38:368-75.
17. Cossman J, Schnitzer B, Deegan MJ. Immunologic surface markers in non-Hodgkin's lymphomas. Am J Pathol 1977; 87:19-32.
18. Pituch-Noworolska A, Drabik G, Kacinska E, et al. Lymphocyte populations in lymph nodes in different histological types of Hodgkin's disease in children. Acta Haematol 2004; 112:129-35.
19. DeVita VT, Jr, Simon RM, Hubbard SM, et al. Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute. Ann Intern Med 1980; 92:587-95.
20. MacLennan K, Bennett M, Tu A, et al. Relationship of histopathologic features to survival and relapse in nodular sclerosing Hodgkin's disease. Cancer 1989; 64:1686-93.
21. Lukes R, Butler J, Hicks E. Natural history of Hodgkin's disease as related to its pathological picture. Cancer 1966; 19:317-44.
22. Wijlhuizen TJ, Vrints LW, Jairam R, et al. Grades of nodular sclerosis (NSI-NSII) in Hodgkin's disease. Are they of independent prognostic value? Cancer 1989; 63:1150-3.
23. Hasenclever D. The disappearance of prognostic factors in Hodgkin's disease. Ann Oncol 2002; 13(suppl 1):75-8.
24. Josting A, Franklin J, May M, et al. New prognostic score based on treatment outcome of patients with relapsed Hodgkin's lymphoma registered in the database of the German Hodgkin's lymphoma study group. J Clin Oncol 2002; 20:221-30.
25. Feltl D, Vitek P, Zamecnik J. Hodgkin's lymphoma in the elderly: the results of 10 years of follow-up. Leuk Lymphoma 2006; 47:1518-22.
26. Allemani C, Sant M, De Angelis R, et al. Hodgkin disease survival in Europe and the U.S.: prognostic significance of morphologic groups. Cancer 2006; 107:352-60.
27. Armstrong AA, Alexander FE, Cartwright R, et al. Epstein-Barr virus and Hodgkin's disease: further evidence for the three disease hypothesis. Leukemia 1998; 12:1272-6.
28. MacMahon B. Epidemiology of Hodgkin's disease. Cancer Res 1966; 26:1189-201.
29. Ashton-Key M, Thorpe PA, Allen JP, et al. Follicular Hodgkin's disease. Am J Surg Pathol 1995; 19:1294-9.
30. Anagnostopoulos I, Hansmann ML, Franssila K, et al. European Task Force on Lymphoma project on lymphocyte predominance Hodgkin disease: histologic and immunohistologic analysis of submitted cases reveals 2 types of Hodgkin disease with a nodular growth pattern and abundant lymphocytes. Blood 2000; 96:1889-99.
31. Shimabukuro-Vornhagen A, Haverkamp H, Engert A, et al. Lymphocyte-rich classical Hodgkin's lymphoma: clinical presentation and treatment outcome in 100 patients treated within German Hodgkin's Study Group trials. J Clin Oncol 2005; 23:5739-45.
32. Swerdlow SH, Campo E, Harris NL, et al. WHO classification of Tumours of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon, France: International Agency for Research on Cancer; 2008.
33. Rudiger T, Jaffe ES, Delsol G, et al. Workshop report on Hodgkin's disease and related diseases ('grey zone' lymphoma). Ann Oncol 1998; 9(suppl 5):S31-8.
34. Garcia JF, Mollejo M, Fraga M, et al. Large B-cell lymphoma with Hodgkin's features. Histpathology 2005; 47:101-10.
35. Pileri S, Bocchia M, Baroni CD, et al. Anaplastic large cell lymphoma (CD30 +/Ki-1+): results of a prospective clinico-pathological study of 69 cases. Br J Haematol 1994; 86:513-23.
36. Jaffe ES. Anaplastic large cell lymphoma: the shifting sands of diagnostic hematopathology. Mod Pathol 2001; 14:219-28.
37. Zinzani PL, Martelli M, Magagnoli M, et al. Anaplastic large cell lymphoma Hodgkin's-like: a randomized trial of ABVD versus MACOP-B with and without radiation therapy. Blood 1998; 92:790-4.
38. Cazals-Hatem D, Andre M, Mounier N, et al. Pathologic and clinical features of 77 Hodgkin's lymphoma patients treated in a lymphoma protocol (LNH87): a GELA study. Am J Surg Pathol 2001; 25:297-306.
39. Dunleavy D, Pittaluga S, Grant N, et al. Gray zone lymphomas: clinical and histological characteristics and treatment with dose-adjusted EPOCH-R. Blood 2008; 112:1228.
40. Oyama T, Ichimura K, Suzuki R, et al. Senile EBV+ B-Cell Lymphoproliferative Disorders: A Clinicopathologic Study of 22 Patients. Am J Surg Pathol 2003; 27:16-26.
41. Mason D, Banks P, Chan J, et al. Nodular lymphocyte predominance Hodgkin's disease: a distinct clinico-pathological entity. Am J Surg Pathol 1994; 18:528-30.
42. Diehl V, Sextro M, Franklin J, et al. Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. J Clin Oncol 1999; 17:776-83.
43. Nogova L, Reineke T, Josting A, et al. Lymphocyte-predominant and classical Hodgkin's lymphoma-comparison of outcomes. Eur J Haematol Suppl 2005; 66:106-10.
44. Lukes RJ, Butler JJ. The pathology and nomenclature of Hodgkin's disease. Cancer Res 1966; 26:1063-83.
45. Poppema S, Kaiserling E, Lennert K. Nodular paragranuloma and progressively transformed germinal centers: ultrastructural and immunohistochemical findings. Virchows Arch [B] 1979; 31:211-25.
46. Ferry JA, Zukerberg LR, Harris NL. Florid progressive transformation of germinal centers. A syndrome affecting young men, without early progression to nodular lymphocyte predominance Hodgkin's disease. Am J Surg Pathol 1992; 16:252-8.
47. Fan Z, Natkunam Y, Bair E, et al. Characterization of variant patterns of nodular lymphocyte predominant hodgkin lymphoma with immunohistologic and clinical correlation. Am J Surg Pathol 2003; 27:1346-56.
48. Rudiger T, Gascoyne RD, Jaffe ES, et al. Workshop on the relationship between nodular lymphocyte predominant Hodgkin's lymphoma and T cell/histiocyterich B cell lymphoma. Ann Oncol 2002; 13(suppl 1):44-51.
49. Boudova L, Torlakovic E, Delabie J, et al. Nodular lymphocyte-predominant Hodgkin lymphoma with nodules resembling T-cell/histiocyte-rich B-cell lymphoma: differential diagnosis between nodular lymphocyte-predominant Hodgkin lymphoma and T-cell/histiocyte-rich B-cell lymphoma. Blood 2003; 102:3753-8.
50. Nam-Cha SH, Roncador G, Sanchez-Verde L, et al. PD-1, a follicular T-cell marker useful for recognizing nodular lymphocyte-predominant Hodgkin lymphoma. Am J Surg Pathol 2008; 32:1252-7.
51. Ekstrand BC, Lucas JB, Horwitz SM, et al. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. Blood 2003; 101:4285-9.
52. Sundeen JT, Cossman J, Jaffe ES. Lymphocyte predominant Hodgkin's disease, nodular subtype with coexistent "large cell lymphoma." Histological progression or composite malignancy? Am J Surg Pathol 1988; 12:599-606.
53. Huang JZ, Weisenburger DD, Vose JM, et al. Diffuse large B-cell lymphoma arising in nodular lymphocyte predominant Hodgkin lymphoma: A report of 21 cases from the Nebraska Lymphoma Study Group. Leuk Lymphoma 2004; 45:1551-7.
54. Chang K-C, Khen NT, Jones D, et al. Epstein-Barr virus is associated with all histological subtypes of Hodgkin lymphoma in Vietnamese children with special emphasis on the entity of lymphocyte predominance subtype. Hum Pathol 2005; 36:747-55.
55. Reed DM. On the pathological changes in Hodgkin's disease, with especial reference to its relation to tuberculosis. Johns Hopkins Hosp Rep 1902; 133-96.
56. Schebesta M, Heavey B, Busslinger M. Transcriptional control of B-cell development. Curr Opin Immunol 2002; 14:216-23.
57. Schubart DB, Rolink A, Kosco-Vilbois MH, et al. B-cell-specific coactivator OBF-1/OCA-B/Bob1 required for immune response and germinal centre formation. Nature 1996; 383:538-42.
58. Krenacs L, Himmelmann AW, Quintanilla-Martinez L, et al. Transcription factor B-cell-specific activator protein (BSAP) is differentially expressed in B cells and in subsets of B-cell lymphomas. Blood 1998; 92:1308-16.
59. Schebesta M, Pfeffer PL, Busslinger M. Control of pre-BCR signaling by Pax5-dependent activation of the BLNK gene. Immunity 2002; 17:473-85.
60. Foss HD, Reusch R, Demel G, et al. Frequent expression of the B-cell-specific activator protein in Reed-Sternberg cells of classical Hodgkin's disease provides further evidence for its B-cell origin. Blood 1999; 94:3108-13.
61. Stein H, Marafioti T, Foss HD, et al. Down-regulation of BOB.1/OBF.1 and Oct2 in classical Hodgkin disease but not in lymphocyte predominant Hodgkin disease correlates with immunoglobulin transcription. Blood 2001; 97:496-501.
62. Torlakovic E, Tierens A, Dang HD, et al. The transcription factor PU.1, necessary for B-cell development is expressed in lymphocyte predominance, but not classical Hodgkin's disease. Am J Pathol 2001; 159:1807-14.
63. McCune RC, Syrbu SI, Vasef MA. Expression profiling of transcription factors Pax-5, Oct-1, Oct-2, BOB.1, and PU.1 in Hodgkin's and non-Hodgkin's lymphomas: a comparative study using high throughput tissue microarrays. Mod Pathol 2006; 19:1010-8.
64. Browne P, Petrosyan K, Hernandez A, et al. The B-cell transcription factors BSAP, Oct-2, and BOB.1 and the pan-B-cell markers CD20, CD22, and CD79a are useful in the differential diagnosis of classic Hodgkin lymphoma. Am J Clin Pathol 2003; 120:767-77.
65. Re D, Muschen M, Ahmadi T, et al. Oct-2 and Bob-1 deficiency in Hodgkin and Reed Sternberg cells. Cancer Res 2001; 61:2080-4.
66. Tzankov A, Bourgau C, Kaiser A, et al. Rare expression of T-cell markers in classical Hodgkin's lymphoma. Mod Pathol 2005; 18:1542-9.
67. Tzankov A, Zimpfer A, Pehrs AC, et al. Expression of B-cell markers in classical hodgkin lymphoma: a tissue microarray analysis of 330 cases. Mod Pathol 2003; 16:1141-7.
68. Pinkus GS, Pinkus JL, Langhoff E, et al. Fascin, a sensitive new marker for Reed-Sternberg cells of hodgkin's disease. Evidence for a dendritic or B cell derivation? Am J Pathol 1997; 150:543-62.
69. Sorg UR, Morse TM, Patton WN, et al. Hodgkin's cells express CD83, a dendritic cell lineage associated antigen. Pathology 1997; 29:294-9.
70. Oudejans JJ, Jiwa NM, Kummer JA, et al. Analysis of major histocompatibility complex class I expression on Reed-Sternberg cells in relation to the cytotoxic Tcell response in Epstein-Barr virus-positive and -negative Hodgkin's disease. Blood 1996; 87:3844-51.
71. Kuppers R, Schwering I, Brauninger A, et al. Biology of Hodgkin's lymphoma. Ann Oncol 2002; 13(suppl 1):11-8.
72. van den Berg A, Visser L, Poppema S. High expression of the CC chemokine TARC in Reed-Sternberg cells. A possible explanation for the characteristic T-cell infiltratein Hodgkin's lymphoma. Am J Pathol 1999; 154:1685-91.
73. Kuppers R, Brauninger A. Reprogramming of the tumour B-cell phenotype in Hodgkin lymphoma. Trends Immunol 2006; 27:203-5.
74. Muschen M, Rajewsky K, Brauninger A, et al. Rare occurrence of classical Hodgkin's disease as a T cell lymphoma. J Exp Med 2000; 191:387-94.
75. Seitz V, Hummel M, Marafoti T, et al. Detection of clonal T-cell receptor gamma-chain gene rearrangements in Reed-Sternberg cells of classic Hodgkin disease. Blood 2000; 95:3020-4.
76. Barry TS, Jaffe ES, Sorbara L, et al. Peripheral T-cell lymphomas expressing CD30 and CD15. Am J Surg Pathol 2003; 27:1513-22.
77. Davis T, Morton C, Miller-Cassman R, et al. Hodgkin's disease, lymphomatoid papulosis, and cutaneous T-cell lymphoma derived from a common T-cell clone. Engl J Med 1992; 326:1115-22.
78. Kuppers R, Hansmann ML. The Hodgkin and Reed/Sternberg cell. Int J Biochem Cell Biol 2005; 37:511-7.
79. Harris NL, Jaffe ES, Stein H, et al. A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994; 84:1361-92.
80. Theil J, Laumen H, Marafioti T, et al. Defective octamer-dependent transcription is responsible for silenced immunoglobulin transcription in Reed-Sternberg cells. Blood 2001; 97:3191-6.
81. Cossman J, Annunziata CM, Barash S, et al. Reed-Sternberg cell genome expression supports a B-cell lineage. Blood 1999; 94:411-6.
82. Kuppers R, Yahalom J, Josting A. Advances in biology, diagnostics, and treatment of Hodgkin's disease. Biol Blood Marrow Transplant 2006; 12(suppl 1):66-76.
83. Kanzler H, Kuppers R, Hansmann ML, et al. Hodgkin and Reed-Sternberg cells in Hodgkin's disease represent the outgrowth of a dominant tumor clone derived from (crippled) germinal center B cells. J Exp Med 1996; 184:1495-505.
84. Marafioti T, Hummel M, Foss HD, et al. Hodgkin and reed-sternberg cells represent an expansion of a single clone originating from a germinal center B-cell with functional immunoglobulin gene rearrangements but defective immunoglobulin transcription. Blood 2000; 95:1443-50.
85. Rajewsky K, Kanzler H, Hansmann ML, et al. Normal and malignant B-cell development with special reference to Hodgkin's disease. Ann Oncol 1997; 8(suppl 2):79-81.
86. Martin-Subero JI, Klapper W, Sotnikova A, et al. Chromosomal breakpoints affecting immunoglobulin loci are recurrent in Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphoma. Cancer Res 2006; 66:10332-8.
87. Bai M, Panoulas V, Papoudou-Bai A, et al. B-cell differentiation immunophenotypes in classical Hodgkin lymphomas. Leuk Lymphoma 2006; 47:495-501.
88. Schwering I, Brauninger A, Klein U, et al. Loss of the B-lineage-specific gene expression program in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2003; 101:1505-12.
89. Hertel CB, Zhou XG, Hamilton-Dutoit SJ, et al. Loss of B cell identity correlates with loss of B cell-specific transcription factors in Hodgkin/Reed-Sternberg cells of classical Hodgkin lymphoma. Oncogene 2002; 21:4908-20.
90. Jox A, Zander T, Kuppers R, et al. Somatic mutations within the untranslated regions of rearranged Ig genes in a case of classical Hodgkin's disease as a potential cause for the absence of Ig in the lymphoma cells. Blood 1999; 93:3964-72.
91. Kuppers R, Schmitz R, Distler V, et al. Pathogenesis of Hodgkin's lymphoma. Eur J Haematol Suppl 2005; (66):26-33.
92. Renne C, Willenbrock K, Kuppers R, et al. Autocrine-and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma. Blood 2005; 105:4051-9.
93. Ushmorov A, Leithauser F, Sakk O, et al. Epigenetic processes play a major role in B-cell-specific gene silencing in classical Hodgkin lymphoma. Blood 2006; 107:2493-500.
94. Cavazzini F, De Wolf-Peeters C, Wlodarska I. Alterations of loci encoding PU.1, BOB1, and OCT2 transcription regulators do not correlate with their suppressed expression in Hodgkin lymphoma. Cancer Genet Cytogenet 2005; 158:167-71.
95. Wang J, Taylor CR. Apoptosis and cell cycle-related genes and proteins in classical Hodgkin lymphoma: application of tissue microarray technique. Appl Immunohistochem Mol Morphol 2003; 11:206-13.
96. Felberbaum RS. The moleular mechanisms of classic Hodgkin's lymphoma. Yale J Biol Med 2005; 78:203-10.
97. Jost PJ, Ruland J. Aberrant NF-kappaB signaling in lymphoma: mechanisms, consequences, and therapeutic implications. Blood 2007; 109:2700-7.
98. Hinz M, Loser P, Mathas S, et al. Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells. Blood 2001; 97:2798-807.
99. Tzankov A, Dirnhofer S. Pathobiology of classical Hodgkin lymphoma. Pathobiology 2006; 73:107-25.
100. Flavell KJ, Murray PG. Hodgkin's disease and the Epstein-Barr virus. Mol Pathol 2000; 53:262-9.
101. Horie R, Watanabe T, Morishita Y, et al. Ligand-independent signaling by overexpressed CD30 drives NF-kappaB activation in Hodgkin-Reed-Sternberg cells. Oncogene 2002; 21:2493-503.
102. Jungnickel B, Staratschek-Jox A, Brauninger A, et al. Clonal deleterious mutations in the IkappaBalpha gene in the malignant cells in Hodgkin's lymphoma. J Exp Med 2000; 191:395-402.
103. Emmerich F, Theurich S, Hummel M, et al. Inactivating I kappa B epsilon mutations in Hodgkin/Reed-Sternberg cells. J Pathol 2003; 201:413-20.
104. Kuppers R. Molecular biology of Hodgkin's lymphoma. Adv Cancer Res 2002; 84:277-312.
105. Mathas S, Lietz A, Anagnostopoulos I, et al. c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis. J Exp Med 2004; 199:1041-52.
106. Kashkar H, Seeger JM, Hombach A, et al. XIAP targeting sensitizes Hodgkin lymphoma cells for cytolytic T-cell attack. Blood 2006; 108:3434-40.
107. Akyurek N, Ren Y, Rassidakis GZ, et al. Expression of inhibitor of apoptosis proteins in B-cell non-Hodgkin and Hodgkin lymphomas. Cancer 2006; 107:1844-51.
108. Chabay P, Pesce P, De Matteo E, et al. No Influence of bcl-2, p53, and p21waf1 protein expression on the outcome of pediatric Hodgkin lymphomas. J Pediatr Hematol Oncol 2006; 28:552-8.
109. Bai M, Papoudou-Bai A, Horianopoulos N, et al. Expression of bcl2 family proteins and active caspase 3 in classical Hodgkin's lymphomas. Hum Pathol 2007; 38:103-13.
110. Stetler-Stevenson M, Crush-Stanton S, Cossman J. Involvement of the bcl-2 gene in Hodgkin's disease. J Natl Cancer Inst 1990; 82:855-8.
111. Dutton A, Young LS, Murray PG. The role of cellular FLICE inhibitory protein (c-FLIP) in the pathogenesis and treatment of cancer. Expert Opin Ther Targets 2006; 10:27-35.
112. Feuerborn A, Moritz C, Von Bonin F, et al. Dysfunctional p53 deletion mutants in cell lines derived from Hodgkin's lymphoma. Leuk Lymphoma 2006; 47:1932-40.
113. Kim LH, Peh SC, Poppema S. Expression of retinoblastoma protein and P16 proteins in classic Hodgkin lymphoma: relationship with expression of p53 and presence of Epstein-Barr virus in the regulation of cell growth and death. Hum Pathol 2006; 37:92-100.
114. Spina D, Leoncini L, Close P, et al. Growth vs. DNA strand breaks in Hodgkin's disease: impaired proliferative ability of Hodgkin and Reed-Sternberg cells. Int J Cancer 1996; 66:179-83.
115. Kuppers R, Sousa AB, Baur AS, et al. Common germinal-center B-cell origin of the malignant cells in two composite lymphomas, involving classical Hodgkin's disease and either follicular lymphoma or B-CLL. Mol Med 2001; 7:285-92.
116. Martin-Subero JI, Knippschild U, Harder L, et al. Segmental chromosomal aberrations and centrosome amplifications: pathogenetic mechanisms in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma? Leukemia 2003; 17:2214-9.
117. Chui DT, Hammond D, Baird M, et al. Classical Hodgkin lymphoma is associated with frequent gains of 17q. Genes Chromosomes Cancer 2003; 38:126-36.
118. Tzankov A, Zimpfer A, Went P, et al. Aberrant expression of cell cycle regulators in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma. Mod Pathol 2005; 18:90-6.
119. Ohsawa M, Fukuhima H, Ikura Y, et al. Expression of cyclooxygenase-2 in Hodgkin's lymphoma: its role in cell proliferation and angiogenesis. Leuk Lymphoma 2006; 47:1863-71.
120. Cossman J, Messineo C, Bagg A. Reed-Sternberg cell: survival in a hostile sea. Lab Invest 1998; 78:229-35.
121. Poppema S, Potters M, Visser L, et al. Immune escape mechanisms in Hodgkin's disease. Ann Oncol 1998; 9(suppl 5):S21-4.
122. Greiner A, Tobollik S, Buettner M, et al. Differential expression of activationinduced cytidine deaminase (AID) in nodular lymphocyte-predominant and classical Hodgkin lymphoma. J Pathol 2005; 205:541-7.
123. Wlodarska I, Nooyen P, Maes B, et al. Frequent occurrence of BCL6 rearrangements in nodular lymphocyte predominance Hodgkin lymphoma but not in classical Hodgkin lymphoma. Blood 2003; 101:706-10.
124. Nishikori M, Uchiyama T. Molecular pathogenesis of Hodgkin lymphoma. Int J Hematol 2006; 83:398-403.
125. Gorschluter M, Bohlen H, Hasenclever D, et al. Serum cytokine levels correlate with clinical parameters in Hodgkin's disease. Ann Oncol 1995; 6:477-82.
126. Skinnider BF, Mak TW. The role of cytokines in classical Hodgkin lymphoma. Blood 2002; 99:4283-97.
127. Atayar C, Poppema S, Blokzijl T, et al. Expression of the T-cell transcription factors, GATA-3 and T-bet, in the neoplastic cells of Hodgkin lymphomas. Am J Pathol 2005; 166:127-34.
128. Ohshima K, Karube K, Hamasaki M, et al. Imbalances of chemokines, chemokine receptors and cytokines in Hodgkin lymphoma: classical Hodgkin lymphoma vs. Hodgkin-like ATLL. Int J Cancer 2003; 106:706-12.
129. Ohshima K, Tutiya T, Yamaguchi T, et al. Infiltration of Th1 and Th2 lymphocytes around Hodgkin and Reed-Sternberg (H&RS) cells in Hodgkin disease: Relation with expression of CXC and CC chemokines on H&RS cells. Int J Cancer 2002; 98:567-72.
130. Gruss HJ, Pinto A, Duyster J, et al. Hodgkin's disease: a tumor with disturbed immunological pathways. Immunol Today 1997; 18:156-63.
131. Chan WC. The Reed-Sternberg cell in classical Hodgkin's disease. Hematol Oncol 2001; 19:1-17.
132. Poppema S. Immunobiology and pathophysiology of hodgkin lymphomas. Hematology (Am Soc Hematol Educ Program) 2005; 231-8.
133. Glimelius I, Edstrom A, Fischer M, et al. Angiogenesis and mast cells in Hodgkin lymphoma. Leukemia 2005; 19:2360-2.
134. Oelmann E, Herbst H, Zuhlsdorf M, et al. Tissue inhibitor of metalloproteinases 1 is an autocrine and paracrine survival factor, with additional immune-regulatory functions, expressed by Hodgkin/Reed-Sternberg cells. Blood 2002; 99:258-67.
135. Pennanen H, Kuittinen O, Soini Y, et al. Clinicopathological correlations of TIMP-1 and TIMP-2 in Hodgkin's lymphoma. Eur J Haematol 2004; 72:1-9.
136. Aldinucci D, Poletto D, Gloghini A, et al. Expression of functional interleukin-3 receptors on Hodgkin and Reed-Sternberg cells. Am J Pathol 2002; 160:585-96.
137. Lee IS, Kim SH, Song HG, et al. The molecular basis for the generation of Hodgkin and Reed-Sternberg cells in Hodgkin's lymphoma. Int J Hematol 2003; 77:330-5.
138. Skinnider BF, Elia AJ, Gascoyne RD, et al. Signal transducer and activator of transcription 6 is frequently activated in Hodgkin and Reed-Sternberg cells of Hodgkin lymphoma. Blood 2002; 99:618-26.
139. Kube D, Holtick U, Vockerodt M, et al. STAT3 is constitutively activated in Hodgkin cell lines. Blood 2001; 98:762-70.
140. Cochet O, Frelin C, Peyron JF, et al. Constitutive activation of STAT proteins in the HDLM-2 and L540 Hodgkin lymphoma-derived cell lines supports cell survival. Cell Signal 2006; 18:449-55.
141. Gruss HJ, Scheffrahn I, Hubinger G, et al. The CD30 ligand and CD40 ligand regulate CD54 surface expression and release of its soluble form by cultured Hodgkin and Reed-Sternberg cells. Leukemia 1996; 10:829-35.
142. Ishida T, Ishii T, Inagaki A, et al. Specific recruitment of CC chemokine receptor 4-positive rgulatory T cells in Hodgkin lymphoma fosters immune privilege. Cancer Res 2006; 66:5716-22.
143. Marshall NA, Christie LE, Munro LR, et al. Immunosuppressive regulatory T cells are abundant in the reactive lymphocytes of Hodgkin lymphoma. Blood 2004; 103:1755-62.
144. Alvaro-Naranjo T, Lejeune M, Salvado-Usach MT, et al. Tumor-infiltrating cells as a prognostic factor in Hodgkin's lymphoma: a quantitative tissue microarray study in a large retrospective cohort of 267 patients. Leuk Lymphoma 2005; 46:1581-91.
145. Asano N, Oshiro A, Matsuo K, et al. Prognostic significance of T-cell or cytotoxic molecules phenotype in classical Hodgkin's lymphoma: a clinicopathologic study. J Clin Oncol 2006; 24:4626-33.
146. Mainou-Fowler T, Taylor PR, Miller S, et al. Intracellular cytokine profiles by peripheral blood CD3+ T-cells in patients with classical Hodgkin lymphoma. Leuk Lymphoma 2003; 44:1325-31.
147. Franzke A, Koenecke C, Geffers R, et al. Classical Hodgkin's lymphoma: molecular evidence for specific alterations in circulating T lymphocytes. Tumour Biol 2006; 27:329-33.
148. Martin SE, Zhang HZ, Magyarosy E, et al. Immunologic methods in cytology: definitive diagnosis of non-Hodgkin's lymphomas using immunologic markers for T-and B-cells. Am J Clin Pathol 1984; 82:666-73.
149. Atayar C, Poppema S, Visser L, et al. Cytokine gene expression profile distinguishes CD4+/CD57+ T cells of the nodular lymphocyte predominance type of Hodgkin's lymphoma from their tonsillar counterparts. J Pathol 2006; 208:423-30.
150. Atayar C, van den Berg A, Blokzijl T, et al. Hodgkin's lymphoma associated T-cells exhibit a transcription factor profile consistent with distinct lymphoid compartments. J Clin Pathol 2007; 60:1092-7.
151. Kerzin-Storrar L, Faed MJ, MacGillivray JB, et al. Incidence of familial Hodgkin's disease. Br J Cancer 1983; 47:707-12.
152. Alexandrescu DT, Garino A, Brown-Balem KA, et al. Anticipation in families with Hodgkin's and non-Hodgkin's lymphoma in their pedigree. Leuk Lymphoma 2006; 47:2115-27.
153. Mack TM, Cozen W, Shibata DK, et al. Concordance for Hodgkin's disease in identical twins suggesting genetic susceptibility to the young-adult form of the disease. N Engl J Med 1995; 332:413-8.
154. Goldin LR, Pfeiffer RM, Gridley G, et al. Familial aggregation of Hodgkin lymphoma and related tumors. Cancer 2004; 100:1902-8.
155. Grufferman S, Cole P, Smith PG, et al. Hodgkin's disease in siblings. N Engl J Med 1977; 296:248-50.
156. Hors J, Dausset J. HLA and susceptibility to Hodgkin's disease. Immunol Rev 1983; 70:167-92.
157. Harty LC, Lin AY, Goldstein AM, et al. HLA-DR, HLA-DQ, and TAP genes in familial Hodgkin disease. Blood 2002; 99:690-3.
158. Diepstra A, Niens M, Vellenga E, et al. Association with HLA class I in Epstein-Barr-virus-positive and with HLA class III in Epstein-Barr-virus- negative Hodgkin's lymphoma. Lancet 2005; 365:2216-24.
159. Chang ET, Montgomery SM, Richiardi L, et al. Number of siblings and risk of Hodgkin's lymphoma. Cancer Epidemiol Biomarkers Prev 2004; 13:1236-43.
160. Campbell GN, Lloyd J, Wotherspoon A, et al. Nodular lymphocyte predominant Hodgkin lymphoma in siblings. Leuk Lymphoma 2004; 45:609-11.
161. Straus SE, Jaffe ES, Puck JM, et al. The development of lymphomas in families with autoimmune lymphoproliferative syndrome with germline Fas mutations and defective lymphocyte apoptosis. Blood 2001; 98:194-200.
162. Keresztes K, Miltenyi Z, Bessenyei B, et al. Association between the Epstein-Barr virus and Hodgkin's lymphoma in the North-Eastern part of Hungary: effects on therapy and survival. Acta Haematol 2006; 116:101-7.
163. Nakatsuka S, Aozasa K. Epidemiology and pathologic features of Hodgkin lymphoma. Int J Hematol 2006; 83:391-7.
164. Araujo I, Bittencourt AL, Barbosa HS, et al. The high frequency of EBV infection in pediatric Hodgkin lymphoma is related to the clasical type in Bahia, Brazil. Virchows Arch 2006; 449:315-9.
165. Andersson J. Epstein-Barr virus and Hodgkin's lymphoma. Herpes 2006; 13:12-6.
166. Chang KC, Huang GC, Jones D, et al. Distribution and prognosis of WHO lymphoma subtypes in Taiwan reveals a low incidence of germinal-center derived tumors. Leuk Lymphoma 2004; 45:1375-84.
167. Cartwright RA, Watkins G. Epidemiology of Hodgkin's disease: a review. Hematol Oncol 2004; 22:11-26.
168. Gulley ML, Eagan PA, Quintanilla-Martinez L, et al. Epstein-Barr virus DNA is abundant and monoclonal in the Reed-Sternberg cells of Hodgkin's disease: association with mixed cellularity subtype and Hispanic American ethnicity. Blood 1994; 83:1595-602.
169. Kis LL, Takahara M, Nagy N, et al. Cytokine mediated induction of the major Epstein-Barr virus (EBV)-encoded transforming protein, LMP-1. Immunol Lett 2006; 104:83-8.
170. Jarrett RF. Viruses and lymphoma/leukaemia. J Pathol 2006; 208:176-86.
171. Niedobitek G, Pazolt D, Teichmann M, et al. Frequent expression of the Epstein-Barr virus (EBV)-induced gene, EBI3, an IL-12 p40-related cytokine, in Hodgkin and Reed-Sternberg cells. J Pathol 2002; 198:310-6.
172. Gandhi MK, Moll G, Smith C, et al. Galectin-1 mediated suppression of Epstein-Barr virus specific T-cell immunity in classic Hodgkin lymphoma. Blood 2007; 110:1326-9.
173. Meyer RM, Ambinder RF, Stroobants S. Hodgkin's lymphoma: evolving concepts with implications for practice. Hematology (Am Soc Hematol Educ Program) 2004; 184-202.
174. Jarrett RF, Stark GL, White J, et al. Impact of tumor Epstein-Barr virus status on presenting features and outcome in age-defined subgroups of patients with classic Hodgkin lymphoma: a population-based study. Blood 2005; 106:2444-51.
175. Claviez A, Tiemann M, Luders H, et al. Impact of latent Epstein-Barr virus infection on outcome in children and adolescents with Hodgkin's lymphoma. J Clin Oncol 2005; 23:4048-56.
176. Keegan TH, Glaser SL, Clarke CA, et al. Epstein-Barr virus as a marker of survival after Hodgkin's lymphoma: a population-based study. J Clin Oncol 2005; 23:7604-13.
177. Herling M, Rassidakis GZ, Medeiros LJ, et al. Expression of Epstein-Barr virus latent membrane protein-1 in Hodgkin and Reed-Sternberg cells of classical Hodgkin's lymphoma: associations with presenting features, serum interleukin 10 levels, and clinical outcome. Clin Cancer Res 2003; 9:2114-20.
178. Kwon JM, Park YH, Kang JH, et al. The effect of Epstein-Barr virus status on clinical outcome in Hodgkin's lymphoma. Ann Hematol 2006; 85:463-8.
179. Ambinder RF, Robertson KD, Moore SM, et al. Epstein-Barr virus as a therapeutic target in Hodgkin's disease and nasopharyngeal carcinoma. Semin Cancer Biol 1996; 7:217-26.
180. Thompson LD, Fisher SI, Chu WS, et al. HIV-associated Hodgkin lymphoma: a clinicopathologic and immunophenotypic study of 45 cases. Am J Clin Pathol 2004; 121:727-38.
181. Spina M, Berretta M, Tirelli U. Hodgkin's disease in HIV. Hematol Oncol Clin North Am 2003; 17:843-58.
182. Pantanowitz L, Schlecht HP, Dezube BJ. The growing problem of non-AIDSdefining malignancies in HIV. Curr Opin Oncol 2006; 18:469-78.
183. Bellas C, Santon A, Manzanal A, et al. Pathological, immunological, and molecular features of Hodgkin's disease associated with HIV infection. Comparison with ordinary hodgkin's disease. Am J Surg Pathol 1996; 20:1520-4.
184. Bosch Princep R, Lejeune M, Salvado Usach MT, et al. Decreased number of granzyme B+ activated CD8+ cytotoxic T lymphocytes in the inflammatory background of HIV-associated Hodgkin's lymphoma. Ann Hematol 2005; 84:661-6.
185. Engels EA, Pfeiffer RM, Goedert JJ, et al. Trends in cancer risk among people with AIDS in the United States 1980-2002. AIDS 2006; 20:1645-54.
186. Rowlings PA, Curtis RE, Passweg JR, et al. Increased incidence of Hodgkin's disease after allogeneic bone marrow transplantation.J Clin Oncol 1999; 17:3122-7.
187. Landgren O, Engels EA, Pfeiffer RM, et al. Autoimmunity and susceptibility to Hodgkin lymphoma: a population-based case-control study in Scandinavia. J Natl Cancer Inst 2006; 98:1321-30.
188. Hjalgrim H, Rasmussen S, Rostgaard K, et al. Familial clustering of Hodgkin lymphoma and multiple sclerosis. J Natl Cancer Inst 2004; 96:780-4.
189. Kamel OW, Weiss LM, van de Rijn M, et al. Hodgkin's disease and lymphoproliferations resembling Hodgkin's disease in patients receiving long-term low-dose methotrexate therapy. Am J Surg Pathol 1996; 20:1279-87.
190. Brown SL, Greene MH, Gershon SK, et al. Tumor necrosis factor antagonist therapy and lymphoma development: twenty-six cases reported to the Food and Drug Administration. Arthritis Rheum 2002; 46:3151-8.
191. Said JW. Immunodeficiency-related Hodgkin lymphoma and its mimics. Adv Anat Pathol 2007; 14:189-94.
192. Jaffe ES, Zarate OA, Medeiros LJ. The interrelationship of Hodgkin's disease and non-Hodgkin's lymphomas-lessons learned from composite and sequential malignancies. Semin Diagn Pathol 1992; 9:297-303.
193. Jaffe ES, Wilson WH. Gray zone, synchronous, and metachronous lymphomas: Diseases at the interface of non-Hodgkin's lymphomas and Hodgkin's Lymphoma. In: Mauch PM, Armitage JO, Coiffier B, et al, eds. Non-Hodgkin's Lymphoma. Philadelphia, PA: Lippincott, Williams, and Wilkins; 2004:69-80.
194. Zarate-Osorno A, Medeiros LJ, Jaffe ES. Hodgkin's disease coexistent with plasma cell dyscrasia. Arch Pathol Lab Med 1992; 116:969-72.
195. Zarate-Osorno A, Medeiros LJ, Kingma DW, et al. Hodgkin's disease following non-Hodgkin's lymphoma. A clinicopathologic and immunophenotypic study of nine cases. Am J Surg Pathol 1993; 17:123-32.
196. Zarate-Osorno A, Medeiros LJ, Longo DL, et al. Non-Hodgkin's lymphomas arising in patients successfully treated for Hodgkin's disease. A clinical, histologic, and immunophenotypic study of 14 cases. Am J Surg Pathol 1992; 16:885-95.
197. Brauninger A, Hansmann ML, Strickler JG, et al. Identification of common germinal-center B-cell precursors in two patients with both Hodgkin's disease and non-Hodgkin's lymphoma. N Engl J Med 1999; 340:1239-47.
198. Momose H, Jaffe ES, Shin SS, et al. Chronic lymphocytic leukemia/small lymphocytic lymphoma with Reed-Sternberg-like cells and possible transformation to Hodgkin's disease. Mediation by Epstein-Barr virus. Am J Surg Pathol 1992; 16:859-67.
199. Fong D, Kaiser A, Spizzo G, et al. Hodgkin's disease variant of Richter's syndrome in chronic lymphocytic leukaemia patients previously treated with fludarabine. Br J Haematol 2005; 129:199-205.
200. Correa P, O'Conor GT. Epidemiologic patterns of Hodgkin's disease. Int J Cancer 1971; 8:192-201.
201. Dinand V, Arya LS. Epidemiology of childhood Hodgkins disease: is it different in developing countries? Indian Pediatr 2006; 43:141-7.
202. Glaser SL, Hsu JL. Hodgkin's disease in Asians: incidence patterns and risk factors in population-based data. Leuk Res 2002; 26:261-9.
203. Gutensohn N, Cole P. Childhood social environment and Hodgkin's disease. N Engl J Med 1981; 304:135-40.
204. Soares A, Biasoli I, Scheliga A, et al. Socioeconomic inequality and short-term outcome in Hodgkin's lymphoma. Int J Cancer 2007; 120:875-9.